Cargando…

Targeted therapies for gastroesophageal cancers

Gastroesophageal cancers are some of the most common malignancies worldwide. A significant portion of patients are diagnosed with advanced or metastatic disease given the insidious nature of gastroesophageal cancers. In the instance where surgical resection for cure is no longer an option, the progn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Andrew, Chudasama, Rani, Almhanna, Khaldoun, Raufi, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Articles on Gastroesophageal Cancer 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576008/ https://www.ncbi.nlm.nih.gov/pubmed/33145323 http://dx.doi.org/10.21037/atm-20-3265

Ejemplares similares

Editorial for the series on gastric and gastroesophageal cancer treatment in 2020
por: Almhanna, Khaldoun
Publicado: (2020)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify off-label use of targeted therapy?—a narrative review
por: Del Prete, Christopher, et al.
Publicado: (2020)

Locoregional gastric cancer: a narrative review of multidisciplinary management
por: Pelcovits, Ari, et al.
Publicado: (2020)

Esophageal cancer in Aleppo, Syria 2010–2020: a rare cancer in a war zone
por: Alhames, Samer, et al.
Publicado: (2020)

Palliative care for patients with esophageal cancer: a narrative review
por: Guyer, Dana L., et al.
Publicado: (2020)

Narrative review of the role of gastroenterologist in the diagnosis, treatment and palliation in gastric and gastroesophageal cancer
por: Diaz, Liege I., et al.
Publicado: (2020)

A narrative review of Barrett’s esophagus in 2020, molecular and clinical update
por: Dam, Aamir N., et al.
Publicado: (2020)

Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment
por: Chudasama, Rani, et al.
Publicado: (2021)

Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
por: Mehta, Rutika, et al.
Publicado: (2018)

Collega's blikken terug op 2020
por: Kluijver, Brenda
Publicado: (2020)

One-Year Toxicity of Ultrahypofractionated Breast Radiotherapy (+/- Sequential Boost) and a Survey of Patient Experience
por: Nicholson, J., et al.
Publicado: (2022)

Beyond Chemotherapy, PD-1, and HER-2: Novel Targets for Gastric and Esophageal Cancer
por: Siddiqui, Ali Zubair, et al.
Publicado: (2021)

Heartburn as a Marker of the Success of Acid Suppression Therapy in Chronic Cough
por: Badri, H., et al.
Publicado: (2021)

Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2016)

Esophageal abnormalities and the risk for gastroesophageal cancers—a histopathology-register-based study in Sweden
por: Ekheden, Isabella, et al.
Publicado: (2022)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Standing on the shoulders of giants: 100 years of neurology and epidemic infections
por: Van Den Tooren, Harriett, et al.
Publicado: (2020)

A 2020 centenary perspective on neuromuscular disorders
por: Goutman, Stephen A, et al.
Publicado: (2020)

Éditorial
por: Giraudeau, B., et al.
Publicado: (2020)

Berichte über die Diskussionen der Studienkomitees der CIGRE
Publicado: (2020)

Ten years to VISION 2020: how are we doing?
por: Ackland, Peter
Publicado: (2010)

Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors
por: Cummings, Donelle, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Using marginal structural joint models to estimate the effect of a time‐varying treatment on recurrent events and survival: An application on arrhythmogenic cardiomyopathy
por: Gregorio, Caterina, et al.
Publicado: (2022)

Evaluation of approaches for accommodating interactions and non‐linear terms in multiple imputation of incomplete three‐level data
por: Wijesuriya, Rushani, et al.
Publicado: (2021)

Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
por: Sousa-Lima, Inês, et al.
Publicado: (2021)

Targeted therapy in gastroesophageal cancers: past, present and future
por: Woo, Janghee, et al.
Publicado: (2015)

The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy
por: Singh, Pradeep K., et al.
Publicado: (2021)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Large rib osteochondroma in a child in Aleppo, Syria
por: Alhames, Samer, et al.
Publicado: (2018)

Optimizing Bariatric Surgery outcomes: the impact of preoperative elevated hemoglobin A1c levels on composite perioperative outcome measures
por: Hart, Alexander, et al.
Publicado: (2020)

Measurement of outflow resistance imposed by magnetic sphincter augmentation: defining normal values and clinical implication
por: Ayazi, Shahin, et al.
Publicado: (2020)

The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318
por: Breakstone, Rimini, et al.
Publicado: (2022)

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma
por: Jiang, Di M., et al.
Publicado: (2020)

The effect of renewable energy on carbon dioxide emission in Taiwan: Quantile mediation analysis
por: Hsu, Tzu-Kuang
Publicado: (2021)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

Evaluation of gastroesophageal reflux disease and hiatal hernia as risk factors for lobectomy complications
por: Kaminski, Michael F., et al.
Publicado: (2022)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mor4lgdmkqgkg601icjdvviant